Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Trevi Therapeutics Inc’s current trading price is -62.86% away from its 52-week high, while its distance from the 52-week low is 13.04%. The stock’s price range over this period has fluctuated between $1.15 and $3.50. The company, operating within the financial sector, had a trading volume of approximately 1.03 million for the day, which was noticeably higher than the average daily share volume of 95080.0 over the last 3 months.
The stock price for Trevi Therapeutics Inc (TRVI) currently stands at $1.30. The stock experienced a substantial increase in the last session, hitting $1.41 after starting at $1.41. The stock’s lowest price was $1.28 before closing at $1.39.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Trevi Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $3.50 on 04/28/23 and the lowest value was $1.15 on 11/13/23.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Trevi Therapeutics Inc (TRVI) has experienced a quarterly decline of -41.70% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 83.02M and boasts a workforce of 25 employees.
Trevi Therapeutics Inc: What Analysts Are Saying
As of right now, 5 analysts are rating Trevi Therapeutics Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.0698, with a change in price of -0.9800. Similarly, Trevi Therapeutics Inc recorded 108,931 in trading volume during the last 100 days, posting a change of -42.98%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for TRVI stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
TRVI Stock Stochastic Average
Today, Trevi Therapeutics Inc’s raw stochastic average for the past 50 days stands at 12.30%, indicating a decline from the raw stochastic average of the last 20 days, which was 20.77%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 30.01% and 32.71% respectively.
TRVI Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -32.64%. However, over the past six months, we’ve seen a stronger performance of -42.98%. The price of TRVI leaped by -27.37% over the last 30 days. And in the last five days, it has fallen by -2.99%.
